Breaking News Instant updates and real-time market news.

REGN

Regeneron

$402.02

-4.34 (-1.07%)

, SNY

Sanofi

$38.19

0.36 (0.95%)

08:45
10/03/16
10/03
08:45
10/03/16
08:45

Regeneron has 'solid' growth prospects, upside potential, says Roth Capital

After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.

REGN

Regeneron

$402.02

-4.34 (-1.07%)

SNY

Sanofi

$38.19

0.36 (0.95%)

  • 07

    Oct

  • 30

    Oct

  • 29

    Mar

REGN Regeneron
$402.02

-4.34 (-1.07%)

08/05/16
LEER
08/05/16
NO CHANGE
Target $511
LEER
Outperform
Regeneron price target lowered to $511 from $530 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Regeneron to $511 from $530, citing cautious guidance following the company's Q2 results. Nonetheless, the analyst points out its Eylea "solid" sales, beating by 2% in the U.S. and 5% overall. The analyst remains positive about Regeneron's product portfolio, strategy, management, and long-term potential. He reiterates an Outperform rating on the shares.
08/05/16
BARD
08/05/16
DOWNGRADE
Target $448
BARD
Neutral
Regeneron downgraded to Neutral at Baird
As reported previously, Baird downgraded Regeneron to Neutral from Outperform. The firm sees risk that the company will not be able to beat earnings consensus over the 2017/18 time frame unless there is a 15-20% downward revision in consensus estimates. Baird lowered its price target to $448 from $505 on Regeneron shares.
09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
SNY Sanofi
$38.19

0.36 (0.95%)

09/08/16
09/08/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Overweight from Neutral at JPMorgan with analyst Chris Schott saying new products could drive upside to 2017 estimates while the risk/reward is favorable into solanezumab data late this year. 2. Johnson Controls (JCI) upgraded to Outperform from Neutral at Macquarie with analyst Mike Wood saying he has increased confidence on the commercial recovery, upside to Tyco synergies, improving cash flow, and potential for further portfolio simplification. 3. Sanofi (SNY) upgraded to Buy from Hold at Berenberg. 4. VMware (VMW) reinstated with Overweight from Neutral at JPMorgan with analyst Mark Murphy saying partner interviews highlight strength in the company's products and Dell has publicly stated that its global distribution network can lead to $1B of incremental VMware revenue. 5. Volaris (VLRS) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/13/16
EXAN
09/13/16
UPGRADE
EXAN
Neutral
Sanofi upgraded to Neutral from Underperform at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Neutral
Sanofi initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started Sanofi with a Neutral rating and EUR 76 price target.

TODAY'S FREE FLY STORIES

CBS

CBS

$59.44

0.01 (0.02%)

, VIAB

Viacom

$31.38

-2.38 (-7.05%)

14:37
01/17/18
01/17
14:37
01/17/18
14:37
Periodicals
Shari Redstone renews push to merge CBS, Viacom, WSJ reports »

Shari Redstone is…

CBS

CBS

$59.44

0.01 (0.02%)

VIAB

Viacom

$31.38

-2.38 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 15

    Feb

JBHT

J.B. Hunt

$120.64

-0.42 (-0.35%)

14:35
01/17/18
01/17
14:35
01/17/18
14:35
Technical Analysis
Technical Earnings Preview: J.B. Hunt near life highs before earnings »

At time of writing and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$31.91

-0.44 (-1.36%)

14:35
01/17/18
01/17
14:35
01/17/18
14:35
Hot Stocks
Deason reports 6% stake in Xerox, demands disclosure of JV pact with Fujifilm »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
01/17/18
01/17
14:35
01/17/18
14:35
General news
Treasury Action: yields held near highs »

Treasury Action: yields…

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

, VNRX

VolitionRx

$2.95

0.0441 (1.52%)

14:31
01/17/18
01/17
14:31
01/17/18
14:31
Hot Stocks
Analysts stay bullish on Exact Sciences after ASCO abstract prompts pullback »

Shares of Exact Sciences…

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

VNRX

VolitionRx

$2.95

0.0441 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 26

    Feb

  • 29

    Mar

AG

First Majestic

$7.36

0.0106 (0.14%)

14:30
01/17/18
01/17
14:30
01/17/18
14:30
Options
Far upside call buyers in First Magestic as shares trade flat »

Far upside call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$71.16

-0.05 (-0.07%)

14:26
01/17/18
01/17
14:26
01/17/18
14:26
Hot Stocks
Vornado raises dividend to 63c per share »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALX

Alexander's

$379.05

-3.045 (-0.80%)

14:24
01/17/18
01/17
14:24
01/17/18
14:24
Hot Stocks
Alexander's boosts quarterly dividend to $4.50 per share »

Alexander's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$147.07

0.21 (0.14%)

14:22
01/17/18
01/17
14:22
01/17/18
14:22
Hot Stocks
USPTO board says Janssen Oncology patent claims unpatentable »

In a final written…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

LOCO

El Pollo Loco

$10.10

-0.2 (-1.94%)

14:20
01/17/18
01/17
14:20
01/17/18
14:20
Options
Bullish option flow in El Pollo Loco »

Bullish option flow in El…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
01/17/18
01/17
14:20
01/17/18
14:20
General news
Fed's Beige Book said the economy continued to expand »

Fed's Beige Book…

$NSD

NASDAQ Market Internals

14:17
01/17/18
01/17
14:17
01/17/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/17/18
01/17
14:16
01/17/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRSP

Crispr Therapeutics

$27.18

-1.34 (-4.70%)

14:12
01/17/18
01/17
14:12
01/17/18
14:12
Recommendations
Crispr Therapeutics analyst commentary  »

Piper says European…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$54.72

0.12 (0.22%)

14:12
01/17/18
01/17
14:12
01/17/18
14:12
Technical Analysis
Technical Earnings Preview: Morgan Stanley near 52-week high before news »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

INTC

Intel

$43.14

-0.1 (-0.23%)

14:10
01/17/18
01/17
14:10
01/17/18
14:10
Options
Large block of puts in Intel as shares advance »

Large block of puts in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

WRB

W. R. Berkley

$70.12

0.7 (1.01%)

14:09
01/17/18
01/17
14:09
01/17/18
14:09
Hot Stocks
W. R. Berkley combines professional liability units »

W. R. Berkley announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ONTX

Onconova

$1.74

-0.0901 (-4.92%)

14:05
01/17/18
01/17
14:05
01/17/18
14:05
Downgrade
Onconova rating change  »

Onconova downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

CY

Cypress Semiconductor

$16.90

-0.17 (-1.00%)

14:05
01/17/18
01/17
14:05
01/17/18
14:05
Options
Cypress Semiconductor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
01/17/18
01/17
14:05
01/17/18
14:05
General news
Apple tax repatriation windfall may total $38 B »

Apple tax repatriation…

14:04
01/17/18
01/17
14:04
01/17/18
14:04
General news
Beige Book says employment, wages grew at modest pace »

The latest Beige Book…

14:03
01/17/18
01/17
14:03
01/17/18
14:03
General news
Fed's Beige Book shows 11 Districts reporting modest to moderate gains »

The Federal Reserve Beige…

TRNC

tronc

$17.97

-0.35 (-1.91%)

14:01
01/17/18
01/17
14:01
01/17/18
14:01
Initiation
tronc initiated  »

tronc initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

ENDP

Endo

$8.01

0.06 (0.75%)

13:55
01/17/18
01/17
13:55
01/17/18
13:55
Options
Endo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
01/17/18
01/17
13:45
01/17/18
13:45
General news
NY Fed accepted $20.55 B in daily reverse repos »

NY Fed accepted $20.55 B…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.